导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.85% | 3559/4773 |
| 近一周 | -3.24% | 3929/5462 |
| 近一月 | -9.36% | 4690/5421 |
| 近一季 | -5.24% | 1794/5209 |
| 近半年 | -11.24% | 3717/4920 |
| 近一年 | -10.93% | 3462/4366 |
| 近两年 | 59.86% | 1216/2954 |
| 近三年 | 11.42% | 1708/2253 |
| 成立以来 | 3.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.09% 3524/4961 |
11.58% 2314/5312 |
- - |
- - |
| 2025 | 13.36% 2646/4813 |
4.81% 878/3635 |
-1.80% 3272/4076 |
22.09% 1698/4524 |
-9.78% 4093/4813 |
| 2024 | 10.69% 1386/3463 |
-5.86% 1961/2808 |
-11.34% 2526/3014 |
18.33% 1023/3129 |
12.08% 189/3463 |
| 2023 | -1.89% 543/2656 |
33.29% 62/2280 |
-8.62% 2007/2385 |
-14.73% 2194/2515 |
-5.53% 1384/2655 |
| 2022 | -24.10% 1188/2207 |
-20.61% 1559/1919 |
-1.84% 1756/2016 |
-13.62% 933/2113 |
12.75% 123/2208 |
| 2021 | 0.21% 721/1822 |
-5.88% 963/1255 |
11.56% 369/1330 |
-7.50% 1056/1466 |
3.18% 465/1822 |
| 2020 | 32.39% 484/1250 |
-1.44% 221/1028 |
27.04% 135/1067 |
2.57% 1002/1164 |
3.09% 945/1184 |
| 2019 | 58.51% 58/1092 |
40.54% 53/754 |
-10.19% 725/804 |
13.00% 28/850 |
11.14% 79/918 |
| 2018 | -39.68% 612/834 |
- - |
- - |
- - |
-14.73% 593/691 |
| 2017 | 20.48% 183/714 |
- - |
- - |
- - |
- - |
| 2016 | -24.12% 468/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证计算机主题ETF联接A VS. 长安沪深300非周期A(740101) |